Literature DB >> 16517803

Acute hepatitis B in the era of immunisation: pitfalls in the identification of high risk patients.

G Rosner1, Y Lurie, L Blendis, Z Halpern, R Oren.   

Abstract

BACKGROUND: Since the adoption of a universal hepatitis B immunisation strategy, the reported incidence of acute hepatitis B has declined dramatically worldwide including in Israel. However, new cases of acute hepatitis B still occur. The aim of this study was to describe the incidence of acute hepatitis B in a referral area, routes of transmission, and outcome.
METHODS: The charts of all new hepatitis B patients, who visited the clinic in the years 2002 and 2003 (January 2002 to December 2003), were reviewed. The main criteria for a diagnosis of acute hepatitis B were transient increase of alanine transaminase activity, and hepatitis B surface antigen seroconversion.
RESULTS: Twenty nine men and seven women were diagnosed with acute hepatitis B infection during the study period. Two patients were previously vaccinated with hepatitis B vaccine. One case of hepatitis D coinfection was reported. The incidence of acute hepatitis B in the referral area was estimated as 2.25 per 100,000 adult population. Mean age was 36 years (17-75). Twenty one patients (18 men and 3 women) acquired the virus through unprotected sexual contact, and seven patients through iatrogenic exposure. Thirty three patients underwent spontaneous seroconversion while three patients became chronic carriers.
CONCLUSIONS: Despite a universal immunisation policy, frequent cases of acute hepatitis B in Israel are still seen. High risk heterosexual activity and iatrogenic exposure seem to be the commonest routes of transmission. Further recommendations regarding vaccination policy are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517803      PMCID: PMC2563707          DOI: 10.1136/pgmj.2005.038778

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  28 in total

1.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.

Authors:  H Hagan; D C Jarlais; S R Friedman; D Purchase; M J Alter
Journal:  Am J Public Health       Date:  1995-11       Impact factor: 9.308

3.  The infected health care provider.

Authors:  J L Gerberding
Journal:  N Engl J Med       Date:  1996-02-29       Impact factor: 91.245

Review 4.  Epidemiology and prevention of hepatitis B.

Authors:  Miriam J Alter
Journal:  Semin Liver Dis       Date:  2003-02       Impact factor: 6.115

Review 5.  Comprehensive control (or elimination) of hepatitis B virus transmission in the United States.

Authors:  F B Hollinger
Journal:  Gut       Date:  1996       Impact factor: 23.059

6.  Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study.

Authors:  A E Williams; R A Thomson; G B Schreiber; K Watanabe; J Bethel; A Lo; S H Kleinman; C G Hollingsworth; G J Nemo
Journal:  JAMA       Date:  1997-03-26       Impact factor: 56.272

7.  Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control.

Authors:  R Harpaz; L Von Seidlein; F M Averhoff; M P Tormey; S D Sinha; K Kotsopoulou; S B Lambert; B H Robertson; J D Cherry; C N Shapiro
Journal:  N Engl J Med       Date:  1996-02-29       Impact factor: 91.245

8.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies.

Authors:  M J Alter; S C Hadler; H S Margolis; W J Alexander; P Y Hu; F N Judson; A Mares; J K Miller; L A Moyer
Journal:  JAMA       Date:  1990-03-02       Impact factor: 56.272

9.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.

Authors:  G B Schreiber; M P Busch; S H Kleinman; J J Korelitz
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

10.  Temporal trends in human immunodeficiency virus seroprevalence and sexual behavior at the San Francisco municipal sexually transmitted disease clinic, 1989-1992.

Authors:  S K Schwarcz; T A Kellogg; R P Kohn; M H Katz; G F Lemp; G A Bolan
Journal:  Am J Epidemiol       Date:  1995-08-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.